Diadema Partners
Latest statistics and disclosures from Diadema Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ABVX, VKTX, BMY, AMGN, UTHR, and represent 36.65% of Diadema Partners's stock portfolio.
- Added to shares of these 10 stocks: ABVX (+$65M), BMY (+$54M), AMGN (+$41M), VKTX (+$32M), NVS (+$24M), KYMR (+$17M), SMMT (+$16M), HIMS (+$14M), BIIB (+$13M), BMRN (+$9.4M).
- Started 43 new stock positions in HIMS, CLDX, Jatt Ii Acquisition Corp, HRTX, ADMA, RIGL, CGON, SYRE, NRIX, BMY.
- Reduced shares in these 10 stocks: , LQDA (-$27M), CYTK (-$19M), APGE (-$19M), UTHR (-$19M), RVMD (-$13M), , , GPCR (-$9.6M), TERN (-$9.6M).
- Sold out of its positions in ABBV, AVXL, APGE, RNA, BBIO, CMPS, Cue Biopharma, CTMX, DNTH, CLYM.
- Diadema Partners was a net buyer of stock by $156M.
- Diadema Partners has $829M in assets under management (AUM), dropping by 41.13%.
- Central Index Key (CIK): 0002026172
Tip: Access up to 7 years of quarterly data
Positions held by Diadema Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Diadema Partners
Diadema Partners holds 116 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Abivax Sa Sponsored Ads Call Option (ABVX) | 12.3 | $102M | +177% | 765k | 133.26 |
|
| Viking Therapeutics (VKTX) | 9.5 | $79M | +69% | 2.0M | 39.01 |
|
| Bristol Myers Squibb Put Option (BMY) | 6.5 | $54M | NEW | 931k | 57.62 |
|
| Amgen Call Option (AMGN) | 4.9 | $41M | NEW | 113k | 362.12 |
|
| United Therapeutics Corporation (UTHR) | 3.5 | $29M | -39% | 53k | 541.83 |
|
| Revolution Medicines (RVMD) | 3.1 | $26M | -32% | 139k | 187.28 |
|
| Uniqure Nv SHS Put Option (QURE) | 3.0 | $25M | -7% | 534k | 46.06 |
|
| Novartis Sponsored Adr Call Option (NVS) | 2.8 | $24M | NEW | 150k | 156.72 |
|
| Kodiak Sciences Call Option (KOD) | 2.6 | $22M | +27% | 562k | 38.96 |
|
| Capricor Therapeutics Com New Put Option (CAPR) | 2.5 | $21M | -16% | 864k | 24.08 |
|
| Cogent Biosciences (COGT) | 2.3 | $19M | +52% | 494k | 38.70 |
|
| Bridgebio Pharma Note 1.750% 3/0 (Principal) | 2.2 | $19M | 250k | 74.48 |
|
|
| Corcept Therapeutics Incorporated Call Option (CORT) | 2.2 | $18M | +22% | 206k | 86.95 |
|
| BioMarin Pharmaceutical (BMRN) | 2.2 | $18M | +111% | 313k | 57.22 |
|
| Kymera Therapeutics Call Option (KYMR) | 2.1 | $17M | NEW | 150k | 114.67 |
|
| Summit Therapeutics Put Option (SMMT) | 2.0 | $16M | NEW | 1.1M | 14.57 |
|
| Hims & Hers Health Com Cl A Put Option (HIMS) | 1.6 | $14M | NEW | 394k | 34.67 |
|
| Replimune Group Call Option (REPL) | 1.6 | $13M | +56% | 1.2M | 11.07 |
|
| Biogen Idec Call Option (BIIB) | 1.6 | $13M | NEW | 60k | 216.06 |
|
| Eli Lilly & Co. Put Option (LLY) | 1.4 | $12M | +66% | 10k | 1199.43 |
|
| Incyte Corporation Put Option (INCY) | 1.4 | $12M | -42% | 105k | 113.36 |
|
| Edgewise Therapeutics (EWTX) | 1.3 | $11M | +28% | 272k | 40.63 |
|
| Arcus Biosciences Incorporated (RCUS) | 1.3 | $11M | +46% | 348k | 30.83 |
|
| Biontech Se Sponsored Ads Call Option (BNTX) | 1.1 | $9.3M | NEW | 100k | 93.05 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 1.1 | $8.8M | +68% | 935k | 9.38 |
|
| Vaxcyte Put Option (PCVX) | 1.0 | $8.5M | +88% | 147k | 58.13 |
|
| Bioage Labs (BIOA) | 1.0 | $8.5M | +477% | 346k | 24.51 |
|
| Immunocore Hldgs Ads (IMCR) | 1.0 | $8.1M | +31% | 255k | 31.75 |
|
| 4d Molecular Therapeutics In (FDMT) | 0.9 | $7.6M | NEW | 571k | 13.30 |
|
| Novo-nordisk A S Adr Put Option (NVO) | 0.9 | $7.5M | +121% | 156k | 47.94 |
|
| Sellas Life Sciences Group I Com New Call Option (SLS) | 0.9 | $7.4M | +66% | 500k | 14.76 |
|
| Moderna Put Option (MRNA) | 0.8 | $7.0M | -37% | 100k | 70.03 |
|
| Corvus Pharmaceuticals (CRVS) | 0.8 | $6.4M | +21% | 428k | 14.94 |
|
| Monte Rosa Therapeutics Call Option (GLUE) | 0.7 | $6.0M | +32% | 249k | 24.20 |
|
| Alumis Call Option (ALMS) | 0.7 | $5.6M | +52% | 200k | 28.14 |
|
| Royalty Pharma Shs Class A Call Option (RPRX) | 0.7 | $5.6M | NEW | 100k | 56.07 |
|
| Johnson & Johnson (JNJ) | 0.7 | $5.6M | -59% | 22k | 253.97 |
|
| Unicycive Therapeutics Com New Call Option (UNCY) | 0.6 | $5.1M | +933% | 1.1M | 4.69 |
|
| Celldex Therapeutics Com New Put Option (CLDX) | 0.6 | $5.1M | NEW | 137k | 37.21 |
|
| Biohaven Call Option (BHVN) | 0.6 | $4.7M | 317k | 14.88 |
|
|
| Vera Therapeutics Cl A (VERA) | 0.6 | $4.6M | NEW | 108k | 42.91 |
|
| Tenax Therapeutics Com New Call Option (TENX) | 0.5 | $4.5M | +70% | 307k | 14.55 |
|
| Relay Therapeutics (RLAY) | 0.5 | $4.3M | NEW | 231k | 18.71 |
|
| Tg Therapeutics Call Option (TGTX) | 0.5 | $4.2M | -63% | 76k | 54.94 |
|
| Zymeworks Del (ZYME) | 0.4 | $3.7M | 142k | 26.14 |
|
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.4 | $3.6M | NEW | 523k | 6.81 |
|
| Intellia Therapeutics Call Option (NTLA) | 0.4 | $3.4M | 200k | 16.92 |
|
|
| Nurix Therapeutics (NRIX) | 0.4 | $2.9M | NEW | 122k | 24.26 |
|
| Indivior Pharmaceuticals (INDV) | 0.3 | $2.8M | -5% | 68k | 41.03 |
|
| Inventiva Sa Ads (IVA) | 0.3 | $2.7M | +110% | 741k | 3.68 |
|
| Oruka Therapeutics (ORKA) | 0.3 | $2.6M | NEW | 28k | 95.17 |
|
| Cytokinetics Com New Put Option (CYTK) | 0.3 | $2.6M | -88% | 30k | 85.19 |
|
| Relmada Therapeutics (RLMD) | 0.3 | $2.5M | +79% | 361k | 6.92 |
|
| Annexon Call Option (ANNX) | 0.3 | $2.2M | -21% | 381k | 5.71 |
|
| Celcuity Call Option (CELC) | 0.3 | $2.1M | -13% | 20k | 104.62 |
|
| Septerna Put Option (SEPN) | 0.2 | $2.0M | +29454% | 60k | 33.49 |
|
| Cybin Com New Call Option (HELP) | 0.2 | $2.0M | NEW | 300k | 6.61 |
|
| Voyager Therapeutics (VYGR) | 0.2 | $2.0M | 564k | 3.50 |
|
|
| Contineum Therapeutics Cl A (CTNM) | 0.2 | $2.0M | NEW | 120k | 16.39 |
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 0.2 | $2.0M | -2% | 463k | 4.24 |
|
| Miragen Therapeutics (VRDN) | 0.2 | $1.8M | NEW | 100k | 18.37 |
|
| Macrogenics (MGNX) | 0.2 | $1.7M | -37% | 374k | 4.62 |
|
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.2 | $1.7M | +414% | 926k | 1.86 |
|
| Adma Biologics Call Option (ADMA) | 0.2 | $1.7M | NEW | 200k | 8.37 |
|
| Spruce Biosciences Com New (SPRB) | 0.2 | $1.6M | +200% | 30k | 54.00 |
|
| Ardelyx (ARDX) | 0.2 | $1.5M | NEW | 303k | 5.10 |
|
| Cue Biopharma (CUE) | 0.2 | $1.5M | NEW | 48k | 31.56 |
|
| Mineralys Therapeutics (MLYS) | 0.2 | $1.5M | +113% | 56k | 26.98 |
|
| Eyepoint Com New Call Option (EYPT) | 0.2 | $1.5M | -62% | 106k | 14.30 |
|
| Prothena Corp SHS (PRTA) | 0.2 | $1.5M | NEW | 150k | 9.79 |
|
| Phathom Pharmaceuticals (PHAT) | 0.2 | $1.4M | +137% | 130k | 10.85 |
|
| Evolus Call Option (EOLS) | 0.2 | $1.4M | +59% | 200k | 6.94 |
|
| Spyre Therapeutics Com New (SYRE) | 0.2 | $1.3M | NEW | 15k | 88.78 |
|
| Cormedix Inc cormedix Put Option (CRMD) | 0.2 | $1.3M | 168k | 7.85 |
|
|
| Editas Medicine Call Option (EDIT) | 0.2 | $1.3M | NEW | 400k | 3.24 |
|
| Equillium (EQ) | 0.2 | $1.3M | -7% | 400k | 3.20 |
|
| Pyxis Oncology Common Stock Call Option (PYXS) | 0.1 | $1.2M | NEW | 388k | 3.01 |
|
| Xeris Pharmaceuticals (XERS) | 0.1 | $1.1M | 133k | 7.92 |
|
|
| Pharvaris N V (PHVS) | 0.1 | $1.0M | 29k | 34.58 |
|
|
| Harmony Biosciences Hldgs In (HRMY) | 0.1 | $978k | -71% | 27k | 36.41 |
|
| Cartesian Therapeutics Com New (RNAC) | 0.1 | $907k | NEW | 87k | 10.42 |
|
| Aquestive Therapeutics Call Option (AQST) | 0.1 | $893k | NEW | 215k | 4.16 |
|
| Rigel Pharmaceuticals (RIGL) | 0.1 | $893k | NEW | 23k | 39.12 |
|
| Elicio Therapeutics Put Option (ELTX) | 0.1 | $829k | NEW | 212k | 3.91 |
|
| Precigen (PGEN) | 0.1 | $771k | +144% | 135k | 5.70 |
|
| Definium Therapeutics Com Shs (DFTX) | 0.1 | $727k | NEW | 16k | 47.04 |
|
| Pelthos Therapeutics Com Shs (PTHS) | 0.1 | $700k | 25k | 28.26 |
|
|
| Pepgen (PEPG) | 0.1 | $672k | +147% | 373k | 1.80 |
|
| Cg Oncology Call Option (CGON) | 0.1 | $519k | NEW | 7.3k | 71.05 |
|
| Enliven Therapeutics (ELVN) | 0.1 | $508k | +3981% | 10k | 50.75 |
|
| Connect Biopharma Hldgs SHS (CNTB) | 0.1 | $469k | 197k | 2.38 |
|
|
| Larimar Therapeutics (LRMR) | 0.1 | $447k | -12% | 147k | 3.05 |
|
| Cellectar Biosciences Com New (CLRB) | 0.0 | $385k | NEW | 138k | 2.78 |
|
| Foghorn Therapeutics (FHTX) | 0.0 | $327k | -16% | 67k | 4.88 |
|
| Aytu Biopharma (AYTU) | 0.0 | $319k | -57% | 149k | 2.15 |
|
| Ocugen (OCGN) | 0.0 | $306k | -60% | 200k | 1.53 |
|
| Inovio Pharmaceuticals Com Shs Call Option (INO) | 0.0 | $303k | -56% | 275k | 1.10 |
|
| Urogen Pharma (URGN) | 0.0 | $263k | -69% | 7.1k | 36.80 |
|
| Heron Therapeutics (HRTX) | 0.0 | $196k | NEW | 459k | 0.43 |
|
| Talphera Com New (TLPH) | 0.0 | $158k | 154k | 1.03 |
|
|
| Monopar Therapeutics Com New (MNPR) | 0.0 | $151k | 1.6k | 92.59 |
|
|
| Lakeland Industries (LAKE) | 0.0 | $151k | NEW | 14k | 10.69 |
|
| Upstream Bio (UPB) | 0.0 | $132k | -11% | 19k | 6.92 |
|
| Meiragtx Holdings Call Option (MGTX) | 0.0 | $120k | NEW | 8.9k | 13.51 |
|
| Jatt Ii Acquisition Corp Ord Shs | 0.0 | $103k | NEW | 9.0k | 11.36 |
|
| Kailera Therapeutics Common Stock | 0.0 | $80k | NEW | 3.6k | 22.03 |
|
| Mannkind Corp Com New (MNKD) | 0.0 | $68k | -91% | 16k | 4.26 |
|
| Entera Bio SHS (ENTX) | 0.0 | $41k | 23k | 1.77 |
|
|
| Silverback Therapeutics (SPRY) | 0.0 | $39k | NEW | 4.9k | 8.01 |
|
| Aprea Therapeutics Com New (APRE) | 0.0 | $36k | NEW | 45k | 0.80 |
|
| Tvardi Therapeutics (TVRD) | 0.0 | $32k | NEW | 17k | 1.90 |
|
| Vistagen Therapeutics Ord Call Option (VTGN) | 0.0 | $13k | -45% | 58k | 0.23 |
|
| Nextcure Com New (NXTC) | 0.0 | $12k | NEW | 7.7k | 1.60 |
|
| Atyr Pharma Com New Put Option (ATYR) | 0.0 | $7.5k | -49% | 13k | 0.60 |
|
| Jade Biosciences Com New Put Option (JBIO) | 0.0 | $3.2k | 1.0k | 3.03 |
|
|
| Erasca Call Option (ERAS) | 0.0 | $1.8k | NEW | 100.00 | 18.32 |
|
Past Filings by Diadema Partners
SEC 13F filings are viewable for Diadema Partners going back to 2025
- Diadema Partners 2026 Q2 filed Aug. 14, 2026
- Diadema Partners 2026 Q1 filed May 15, 2026
- Diadema Partners 2025 Q4 filed Feb. 17, 2026
- Diadema Partners 2025 Q3 filed Nov. 14, 2025